AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome [Yahoo! Finance]
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
Down's Syndrome Market to Exhibit Growth at a CAGR of 3.81% by 2034 | DelveInsight [Yahoo! Finance]
AC Immune's stock jumps after Parkinson's therapy shows signs of benefit [Yahoo! Finance]
AC Immune SA (NASDAQ: ACIU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.